PR Newswire

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

By {fullname}

Today, 18:00 11 read

Font size Print

{fullname}

About author

You should write because you love the shape of stories and sentences and the creation of different words on a page.

View all posts

---

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 17, 2025 /PRNewswire/ -- Harbour BioMed (HKEX:

---

Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare

SHANGHAI, Dec. 19, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company")

---

Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

BENGALURU, India, Jan. 21, 2026 /PRNewswire/ -- Syngene International, a global contract research,

---

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help

---

NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 25, 2026 /PRNewswire/

---

Providence Therapeutics Announces Appointment of Leah Goodman to the Board of Directors

Leah Goodman brings a wealth of policy and regulatory experience and is a recognized leader in Australia for

---

Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the

---

Servier completes the acquisition of Day One Biopharmaceuticals

Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S . in

---

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a

Viet Reader.

Viet Reader.

VR.

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

{fullname}

About author

Today Highlight

Supermicro Expands End-to-End DCBBS Liquid Cooling Portfolio with Rear Door Heat Exchangers for High-Density AI and HPC Infrastructure

Media join forces to shape shared narrative

Aiper Launches Aiper Anniversary 2026 -- A New Annual Member Celebration with Exclusive Savings, Trade-In Rewards and Loyalty Benefits

Dao by Dorsett AMTD Singapore Honoured with Tripadvisor Travellers' Choice 2026, Recognised Among the Top 10% of Properties Worldwide

Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS

Most Popular

OlloBot Reveals OlloNi SS1's New Identity Design and Announces Ollo-Family Blind Box Launch at Houston Pop-Up This July

Meet Cutting-Edge Slimness: Baseus PicoGo Air, the Thinnest Addition to Baseus PicoGo Series

PrimeBOT Brings Personal Robotics to the UN's AI for Good Summit in Geneva

AlgoLaser Launches DIY KIT MK3: Start, Just That Simple--A Smarter Way to Laser Engrave

OPPO and realme Extend and Expand Partnership with Taboola, Bringing Taboola News to Millions More Smartphones Globally

Newsletter

Viet Reader.

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

About author

Related posts

Today Highlight

Most Popular

Newsletter